News
Dr. David H. Farrell, to Speak at American Heart Association Conference in Chicago
April 29, 2011

Gamma Therapeutics Founder and CSO, Dr. David H. Farrell, to Speak at American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2011 Conference in Chicago, IL

Dr. Farrell’s talk presents the strong correlation between Gamma Prime Fibrinogen, a natural occurring protein in human blood, and cardiovascular and coronary heart disease.

April 29, 2011–Portland, Oregon-Gamma Therapeutics, Inc., an Oregon biotech venture developing diagnostic test and surgical therapy solutions for the cardiovascular disease (CVD) industry, announced today that Dr. David H. Farrell, GT’s Founder and CSO, and a professor of medicine in the OHSU Division of Cardiovascular Medicine will present scientific research related to his three decades of research in fibrinogen, hemostasis and thrombosis in the human body at the Annual American Heart Association ATVB Conference in Chicago, IL, April 28-30, 2011.

Titled, “Genome-Wide Association Study of γ’ Fibrinogen Levels in the Framingham Offspring Cohort (1),” Dr. Farrell’s talk focuses on Gamma Prime Fibrinogen, a naturally occurring clotting protein in human blood. Gamma Prime Fibrinogen is a carrier protein for Factor XIII zymogen; a thrombin binding site; forms clots that are resistant to fibrinolysis, and; has been shown to have a strong and significant correlation with cardiovascular and coronary heart disease.

The Framingham Heart Study, inaugurated in 1947, is currently the longest continuing study of cardiovascular disease risk in the world. The most recent studies by Dr. David Farrell, the Framingham investigators and Dr. Rehana Lovely, Missouri State University, was published in the Journal of Clinical Chemistry 2010:56:781-8, and titled, “γ’ Fibrinogen: Evaluation of a New Assay for Study of Associations with Cardiovascular Disease.” (2)

Leading cardiovascular disease research, such as the Framingham Heart Study (2), the Stockholm Coronary Artery Risk Factor Study (3), and the Penn State University CAD Study (4) continue to focus on coronary heart disease, heart attack, and their causes, with the goal of developing new diagnostic cardiac biomarkers, therapies, and preventative care programs to reduce mortality.

Dr. Farrell has applied his CVD research and launched a new diagnostic test and surgical therapy venture start-up called Gamma Therapeutics with the goal of developing and commercializing a novel cardiovascular risk assay called GammaCoeur™, based upon the use of Gamma Prime Fibrinogen as a potential cardiac biomarker for heart attack and stroke.

According to Dr. Farrell, “We believe the GammaCoeur CVD Risk Assay will one day be a diagnostic test of choice for physicians, along with traditional tests in use today, assisting them in better predicting cardiac events and implementing preventative care programs to treat patient disease before costly drug regimens and invasive cardiac surgery are required.”

About Gamma Therapeutics, Inc.
Gamma Therapeutics (GT) is an Oregon early stage biotechnology venture developing a novel class of diagnostic test and surgical therapy solutions for the cardiovascular disease industry. Patented and patent-pending GT products under development include the GammaCoeur CVD Risk Assay, the GammaSeal™ Surgical Incision Sealant, and the Gammarin™ Anticoagulant Blood Thinner. Gamma Therapeutics is headquartered at 2611 SW Third Avenue, Suite 280N, Portland, Oregon 97201. For more information, go to the Gamma Therapeutics website at: www.gamma-therapeutics.com

Media Contact:

David Eastman, CEO
deastman@gamma-therapeutics.com
503.222.2313

(1) ATVB Presentation: “Genome-Wide Association Study of γ’ Fibrinogen Levels in the Framingham Offspring Cohort, ” David H Farrell, Oregon Health & Science University; Rehana S Lovely, Missouri State Univ, Springfield, MO; Qiong Yang, Joseph M Massaro, Ralph B D’Agostino, Boston Univ, Boston, MA; Christopher J O’Donnell, Framingham Heart Study, Framingham, MA; Jackilen Shannon, Oregon Health & Science Univ,

Study References:

(1) Framingham Heart Study: Lovely et al. γ’ Fibrinogen: Evaluation of a New Assay for Study of Associations with Cardiovascular Disease. Clinical Chemistry 2010; 56: 781-8
(2) Stockholm Coronary Artery Risk Factor Study: Mannila et al. Elevated Plasma Fibrinogen γ’ Concentration Increases Risk of Myocardial Infarction: Effects of Genetic Variation in Fibrinogen Genes and Environmental Factors.  Journal of Thrombosis and Haemostasis 2007; 5: 766-73
(3) Penn State University CAD Study: Lovely et al. Association of γA/γ’ Fibrinogen Levels and Coronary Artery Disease.  Thrombosis and Haemostasis 2002; 88: 26-31

™GammaCoeur, GammaSeal, Gammarin, the products, and Gamma Therapeutics, the company name, letter type and logomark, are trademarks of Gamma Therapeutics, Inc., Portland, Oregon. All Rights Reserved ©Copyright, 2011



Gamma Therapeutics Awarded Phase II Research Grant
April 19, 2011

PRESS RELEASE

Gamma Therapeutics Awarded Phase II NIH Small Business Innovation Research Grant to Develop GammaCoeur™, a Novel Cardiovascular Disease Risk Test

April 19, 2011–Portland, Oregon-Gamma Therapeutics, Inc., an Oregon biotech venture developing diagnostic test and surgical therapy solutions for the cardiovascular disease (CVD) industry, announced today that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH),to commercialize its GammaCoeur CVD Risk Assay.

The $1.1 million commercialization grant will allow Gamma Therapeutics to complete development, validation and BETA testing of GammaCoeur; submit its FDA regulatory approval application for a Class II

In Vitro Diagnostic Device and market the product globally when approved. The Company estimates regulatory approval will take up to two years, although it is working toward approval by end of 2012.

GammaCoeur CVD Risk Assay. All Gamma Therapeutic CVD products are based upon a naturally occurring protein in human blood, responsible for the clotting mechanism, called Gamma Prime Fibrinogen. Gamma Prime Fibrinogen has been shown in a host of scientific studies (1,2,3) to be strongly and significantly associated with cardiovascular disease. GammaCoeur addresses the need for a new heart attack and stroke risk biomarker to complement traditional diagnostic tests in use today, such as those to determine cholesterol, triglycerides and glucose levels. Worldwide, millions die each year from fatal heart attacks, many of which were preventable with better predictive data. In 2009 alone, of the 500,000 Americans who died of a heart attack, 50% tested normal for cholesterol, a test considered the gold standard for heart risk assessment.

According to Dr. David H. Farrell, Gamma Therapeutics’ Founder and Chief Science Officer, “Leading cardiovascular disease research institutions, such as the Framingham Heart Study, and others continue to research coronary disease, heart attack, and their causes, with the goal of developing new therapies and preventative care programs to reduce mortality. GammaCoeur, when approved for use, will enhance this effort by giving primary care physicians and cardiologists a better predictive and prognosis tool for assessing patient risk.”

“We completed our Phase I grant milestone for the GammaCoeur CVD Risk Assay, the development of a working prototype in less than six months, and this success and proof of concept supported the NIH’s granting of the Phase II grant monies,” stated David F. Eastman, Gamma Therapeutics’ CEO.

According to Gamma Therapeutic executives, other patented and patent-pending products in the product pipeline include GammaSeal™, a surgical incision sealant, and Gammarin™, an anti-coagulant blood thinner for control of venous thromboembolism (VTE).

About Gamma Therapeutics, Inc.
Gamma Therapeutics is an Oregon “C” corporation and biotechnology venture start-up developing a novel class of diagnostic test and surgical therapy solutions for the cardiovascular disease industry. Gamma Therapeutics’s corporate offices and laboratory are headquartered in the Marquam II Building, 2611 SW Third Avenue, Suite 280N, Portland, Oregon 97201. For more information, go to the Gamma Therapeutics website at: www.gamma-therapeutics.com

Media Contacts:

David Eastman, CEO
deastman@gamma-therapeutics.com
503.222.2313

Study References:

(1) Framingham Heart Study: Lovely et al. ‘ Fibrinogen: Evaluation of a New Assay for Study of Associations with Cardiovascular Disease. Clinical Chemistry 2010; 56: 781-8
(2) Stockholm Coronary Artery Risk Factor Study: Mannila et al. Elevated Plasma Fibrinogen ’ Concentration Increases Risk of Myocardial Infarction: Effects of Genetic Variation in Fibrinogen Genes and Environmental Factors. Journal of Thrombosis and Haemostasis 2007; 5: 766-73
(3) Penn State University CAD Study: Lovely et al. Association of A/’ Fibrinogen Levels and Coronary Artery Disease. Thrombosis and Haemostasis 2002; 88: 26-31

™GammaCoeur, GammaSeal, Gammarin, the products, and Gamma Therapeutics, the company name, letter type and logomark, are trademarks of Gamma Therapeutics, Inc., Portland, Oregon. All Rights Reserved ©Copyright, 2010



Health Diagnostic Laboratory, Inc Partners with GT
March 1, 2011

Media Alert

Health Diagnostic Laboratory, Inc (HDL, Inc.) Partners with Gamma Therapeutics to offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk

March 1, 2011– Richmond, Virginia — Health Diagnostic Laboratory Inc. (HDL, Inc.), www.myhdlab.com, announced today its partnership to develop a novel laboratory developed test with Gamma Therapeutics, Inc., an Oregon-based biotechnology venture developing diagnostic test and surgical therapy solutions for the cardiovascular disease industry.

Cardiovascular disease (CVD), coronary heart disease (CHD) and stroke are responsible for 16.7 million, or 29.9% of total global deaths associated with some type of disease, according to the World Health Organization. In 2010, CVD became the leading cause of death in developing countries. At least 20 million people survive heart attacks and strokes every year; many require continuing costly clinical care.

Gamma Therapeutics, launched in November 2010, is bringing to market, in a joint product development effort with HDL, Inc., a novel CVD Risk Assay to enhance cardiologists’ ability to assess heart attack and stroke risk by providing a new predictive and prognostic tool.  The laboratory developed CVD Risk Assay is based upon a naturally occurring clotting protein in human blood called Gamma Prime Fibrinogen, a biomarker strongly associated with cardiovascular disease.  The laboratory developed test version of the Gamma Therapeutics’ CVD Assay will be offered exclusively by HDL, Inc., who also will take the lead in BETA testing of the assay for FDA approval.

The Gamma Therapeutics’ executive management team includes David H. Farrell, Ph.D., Founder and CSO and David F. Eastman, M.Sc., CEO. Its science advisory board is comprised of leading scientists in cardiovascular disease, pathology and hematology research, with expertise in CVD patient medicine and preventative care, cardiovascular surgery, heart attack and stroke risk assessment, clinical and diagnostic testing, surgery-based treatment and business experience in growing biotechnology and medical device ventures.

The launch of the partnership between HDL, Inc. and Gamma Therapeutics represents a combined effort to advance the preventative model for chronic disease management, based on a recent monumental shift in the way physicians test for life-threatening conditions. Moving beyond traditional lipid testing, HDL. Inc. is a market leader in providing comprehensive diagnostics capable of detecting risk factors predisposing patients to cardiovascular disease earlier than ever before possible.

“The results are simple,” said Tonya Mallory, CEO and founder of Virginia-headquartered HDL, Inc. “Thanks to advanced testing, it’s now possible to reveal risk factors and biomarkers for cardiovascular and related diseases. The partnership with Gamma Therapeutics demonstrates HDL, Inc.’s on-going goal to provide best of breed biomarkers, such as this new assay.”  Using a systematic approach to identify factors contributing to disease allows HDL, Inc. to provide its physicians with a better basis for effective treatment plans.

About HDL, Inc.
Health Diagnostic Laboratory Inc. (HDL, Inc.), a CAP accredited leader in health management, offers a comprehensive test menu of risk factors and biomarkers for cardiovascular and related diseases. Our systematic approach identifies factors contributing to disease and provides a basis for effective personalized treatment, allowing physicians to more effectively manage patients.  As an added value, patients receive a personalized overview of their risk factors along with intensive counseling from expert Health Coaches at no additional cost, improving compliance and enhancing potential outcomes. For more information, www.myhdl.com.

About Gamma Therapeutics, Inc.
Gamma Therapeutics, Inc., is an Oregon biotechnology venture developing a novel class of diagnostic test and surgical therapy solutions for the cardiovascular disease industry.
All of its products are based upon a natural protein in blood called Gamma Prime Fibrinogen. Patent-pending and patented products under development include the GammaCoeur™ CVD Risk Assay, GammaSeal™ Surgical Incision Sealant and Gammarin™ Anti-Coagulant Blood Thinner. Gamma Therapeutics’ corporate offices and laboratory are headquartered at 2611 SW Third Avenue, Suite 280N, Portland, Oregon 97201. For more information, www.gamma-therapeutics.com.

Media Contact:  David Eastman, CEO, Gamma Therapeutics, Inc., deastman@gamma-therapeutics.com



GT Appoints Prestigious Board of Science Advisors to Guide Product Development
February 1, 2011

February 1, 2011–Portland, Oregon-Gamma Therapeutics, Inc., an Oregon-based biotechnology venture developing biopharmaceutical and diagnostic test solutions for the cardiovascular disease (CVD) industry, announced today the appointment of its new Board of Science Advisors (BOSA) selected to guide the company’s research and product development efforts.

Gamma Therapeutics launched the company in November, 2010 and is developing a host of new commercial products to address the need for point-of-care diagnostics and post-surgical therapy in the fast growing CVD industry. The flagship product, GammaCoeur™, based upon a naturally occurring protein in human blood called Gamma Prime Fibrinogen, is a novel CVD diagnostic assay for heart attack and stroke risk.

Board of Science Advisors Bring Broad Experience in Cardiovascular Disease.  The Gamma Therapeutics’ executive management team, David H. Farrell, Ph.D., Founder and CSO and David Eastman, M.Sc., CEO and its science advisory board are comprised of leading scientists in cardiovascular disease, pathology and hematology research, with  expertise in CVD patient medicine and preventative care, cardiovascular surgery, heart attack and stroke risk assessment, clinical and diagnostic testing, surgery-related treatment and business experience in building, growing and managing biotechnology and medical device ventures.

The Gamma Therapeutics BOSA members include:
Kent Thornburg, Ph.D., M. Lowell Edwards Professor of Medicine, Director, Heart Research Center, Oregon Health & Science University
Sanjiv Kaul, M.D., Professor and Division Head, Division of Cardiovascular Medicine, Department of Medicine, Oregon Health & Science University
Steven Kazmierczak, Ph.D., Professor and Director, Clinical Chemistry & Toxicology, Department of Pathology, Oregon Health & Science University
Martin Schreiber, M.D., Professor of Surgery, Chief, Division of Trauma, Critical Care and Acute Care Surgery, Director of Adult ICUs, Oregon Health & Science University
José López, M.D., Executive Vice President for Research, Puget Sound Blood Center, Research Division

David Farrell and I are truly honored to have a highly experienced Board of Science Advisors provide their insight and guidance as we build the company and focus our product development efforts on novel medical devices and biopharmaceuticals for the CVD industry,” commented David F. Eastman, chief executive officer. “With our BOSA, it is Gamma Therapeutics’ mission to develop solutions for point-of-care diagnostics, preventative care medicine and surgery-related therapies that enhance patient quality of care and treatment outcomes.”

In August, 2010, Gamma Therapeutics received a $1.46 M, 3-year National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Grant to develop GammaCoeur. The first prototype assay is under development and the company hopes to begin BETA testing in early 2011 as part of the FDA’s in vitro diagnostic device approval process.

According to Gamma Therapeutics executives, other patented and patent-pending products under commercial development include: GammaSeal™, a high strength, surgical sealant, and Gammarin™, an anti-coagulant blood thinner.  The company will seek additional SBIR grants in 2011 for development.

About Gamma Therapeutics
Gamma Therapeutics, Inc. is a Oregon “C” corporation and biotechnology venture start-up developing a novel class of biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry. Gamma Therapeutics’s corporate offices and laboratory are headquartered in the Marquam II Building,  2611 SW Third Avenue, Suite 280N, Portland, Oregon 97201. For more information, go to the
Gamma Therapeutics website at: www.gamma-therapeutics.com

Media Contacts:

David Eastman, CEO
deastman@gamma-therapeutics.com
503.222.2313



Gamma Therapeutics Introduces New Cardiovascular Disease Test.
November 18, 2010

Gamma Therapeutics Launches Biotechnology Venture to Develop Novel Cardiovascular Disease Risk Diagnostic Test

November 18, 2010-Portland, Oregon-Gamma Therapeutics, Inc., an Oregon-based biotechnology venture developing biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry, announced today the launch of its new corporate headquarters and research laboratory in Portland, Oregon. Gamma Therapeutics’  products are based upon a natural clotting protein in human blood, called Gamma Prime Fibrinogen. The flagship product, branded GammaCoeur(TM), is a novel cardiovascular disease risk diagnostic test.

GammaCoeur Cardiovascular Disease Risk Diagnostic Assay. GammaCoeur addresses the need for a new cardiovascular disease (CVD) test to complement traditional testing methods, such as those to determine cholesterol, triglyceride and glucose levels for heart attack and stroke risk.  Worldwide, millions die each year from fatal heart attacks, many of which may have been preventable with more predictive testing methods.  In fact, in 2009, of the 500,000 Americans who died of a heart attack, as many as 50% tested normal for cholesterol levels, the recognized gold standard for heart risk assessment. The target audience for GammaCoeur includes cardiologists, cardiovascular physicians and hematologists.

Gamma Therapeutics’ founder, Dr. David Farrell, formerly an Oregon Health & Science University (OHSU) pathology professor and researcher and, currently, a professor of medicine in the OHSU Division of Cardiovascular Medicine, will assume a new position in the company as Chief Scientific Officer (CSO).

According to Dr. Farrell, “During our research over the past 10 years and as part of ongoing heart studies by leading cardiovascular research institutions, such as the Framingham Heart Study (1) and others (2,3), strong and significant links were found between Gamma Prime Fibrinogen levels and cardiovascular disease.  The GammaCoeur CVD Risk Assay, built upon the Gamma Prime Fibrinogen platform, will enhance cardiologists’ ability to assess heart attack and stroke risk, provide a new predictive tool for point-of-care diagnostics and improve the quality and outcomes of preventative medicine.”

Gamma Therapeutics Wins $1.46 M NIH/SBIR Award. In August, 2010, Gamma Therapeutics received a $1.46 M, 3-year National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Grant to develop GammaCoeur. The first prototype assay is currently under development, and the company hopes to begin BETA testing in early 2011 as part of the FDA medical device approval process.

David Eastman, a life science and medical device industry veteran and consultant for 24 medical and biotechnology venture start-ups has joined Gamma Therapeutics as the new Chief Executive Officer.  Formerly the interim CEO of Yecuris Corporation, an OHSU biotech venture developing humanized mice for drug discovery, Eastman brings to the company 25 years of national and international experience in the business development, funding and commercialization of biotech and medical device products.

“We are excited about launching a new Oregon biotechnology company and developing a novel heart risk assay for the cardiovascular industry. In the U.S. alone, over $500 billion is spent annually on cardiovascular disease-related problems of which $1.36 B is spent on diagnostic testing,” commented David Eastman, chief executive officer. “GammaCoeur will give physicians a better prognosis tool to assess heart attack or stroke risk and offer the potential to lower the cost of care and treatment.”

According to Gamma Therapeutic executives, other patented and patent-pending products in the product pipeline include GammaSeal™, a surgical sealant, and Gammarin™, an anti-coagulant blood thinner. 

About Gamma Therapeutics, Inc.

Gamma Therapeutics, Inc. is a Oregon “C” corporation and biotechnology venture start-up developing a novel class of biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry. Gamma Therapeutics’s corporate offices and laboratory are headquartered in the Marquam II Building,  2611 SW Third Avenue, Suite 280N, Portland, Oregon 97201. For more information, go to the Gamma Therapeutics website at: www.gamma-therapeutics.com

Media Contacts:

David Eastman, CEO

deastman@gamma-therapeutics.com

503.222.2313

Study References:

(1)   Framingham Heart Study: Lovely et al. γ’ Fibrinogen: Evaluation of a New Assay for Study of Associations with Cardiovascular Disease. Clinical Chemistry 2010; 56: 781-8

(2)   Stockholm Coronary Artery Risk Factor Study: Mannila et al. Elevated Plasma Fibrinogen γ’ Concentration Increases Risk of Myocardial Infarction: Effects of Genetic Variation in Fibrinogen Genes and Environmental Factors.  Journal of Thrombosis and Haemostasis 2007; 5: 766-73

(3)   Penn State University CAD Study: Lovely et al. Association of γA/γ’ Fibrinogen Levels and Coronary Artery Disease.  Thrombosis and Haemostasis 2002; 88: 26-31

###

™GammaCoeur, GammaSeal, Gammarin, the  products, and  Gamma Therapeutics, the company name, letter type and logomark,

are trademarks of  Gamma Therapeutics, Inc., Portland, Oregon. All Rights Reserved ©Copyright, 2010



Copyright © 2010, Gamma Therapeutics, Inc. All rights reserved.